Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 4;13(1):301.
doi: 10.3390/jcm13010301.

Choice and Duration of Anticoagulation for Venous Thromboembolism

Aroosa Malik  1 , Nghi B Ha  2 , Geoffrey D Barnes  1
Affiliations
Review

Choice and Duration of Anticoagulation for Venous Thromboembolism

Aroosa Malik et al. J Clin Med. .

Abstract

Venous thromboembolism (VTE) is a prevalent medical condition with high morbidity, mortality, and associated costs. Anticoagulation remains the main treatment for VTE, though the decision on when, how, and for how long to administer anticoagulants is increasingly complex. This review highlights the different phases of VTE management, with special circumstances for consideration such as antiphospholipid syndrome, coronary artery disease, cancer-associated thrombus, COVID-19, and future anticoagulation options. Anticoagulation management will continue to be a complex decision, applying evidence-based medicine to individual patients with the hope of maximizing effectiveness while minimizing risks.

Keywords: anticoagulation; cardio-vascular disease; deep vein thrombosis; pulmonary embolism; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

GDB: Grant Funding—Boston Scientific; Consulting—Pfizer, Bristol-Myers Squibb, Janssen, Bayer, AstraZeneca, Sanofi, Anthos, Abbott Vascular, Boston Scientific; DSMB—Translational Sciences (Clinical Events Adjudication Committee); Board of Directors—Anticoagulation Forum. AM and NH—none.

Figures

Figure 1
Figure 1
Choice and duration of anticoagulation for VTE.
Figure 2
Figure 2
VTE and CAD antithrombotic therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Beckman M.G., Hooper W.C., Critchley S.E., Ortel T.L. Venous thromboembolism: A public health concern. Am. J. Prev. Med. 2010;38((Suppl. S4)):S495–S501. doi: 10.1016/j.amepre.2009.12.017. - DOI - PubMed
    1. CDC Data and Statistics on Venous Thromboembolism. [(accessed on 6 November 2023)]; Available online: https://www.cdc.gov/ncbddd/dvt/data.html.
    1. Kearon C., Ageno W., Cannegieter S.C., Cosmi B., Geersing G.J., Kyrle P.A. Categorization of patients as having provoked or unprovoked venous thromboembolism: Guidance from the SSC of ISTH. J. Thromb. Haemost. 2016;14:1480–1483. doi: 10.1111/jth.13336. - DOI - PubMed
    1. Renner E., Barnes G.D. Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar. J. Am. Coll. Cardiol. 2020;76:2142–2154. doi: 10.1016/j.jacc.2020.07.070. - DOI - PubMed
    1. Stevens S.M., Woller S.C., Baumann Kreuziger L., Bounameaux H., Doerschug K., Geersing G.-J., Huisman M.V., Kearon C., King C.S., Knighton A.J., et al. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160:2247–2259. doi: 10.1016/j.chest.2021.07.056. - DOI - PubMed

LinkOut - more resources